# LEO Pharma

Source: https://onco.cc/companies/leo-pharma/  
OnCo record `leo-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LEO Pharma is a foundation-owned Danish dermatology company whose cancer-related trials concern actinic keratosis, the precancerous skin lesion that can progress to squamous cell carcinoma.

## Summary

LEO Pharma, based in Ballerup near Copenhagen and majority-owned by the LEO Foundation, specialises in medical dermatology. Its registry footprint in cancer comes from actinic keratosis, the sun-damage lesion that can progress to cutaneous squamous cell carcinoma: it marketed ingenol mebutate gel (Picato) for the condition until the product's EU authorisation was withdrawn in 2020 over a possible skin cancer signal. OnCo records it so that those phase 3 trials resolve to a sponsor page.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: LEO Pharma A/S
- Tags: ctgov-sponsor
- HQ: Ballerup
- Type: pharma
- Website: https://www.leo-pharma.com

## Sources

- Official website: https://www.leo-pharma.com
- ClinicalTrials.gov: trials led by LEO Pharma: https://clinicaltrials.gov/search?lead=LEO%20Pharma
- Wikipedia: https://en.wikipedia.org/wiki/LEO_Pharma

## Connected records

- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/)

---
JSON: https://onco.cc/api/v1/entities/leo-pharma.json